Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/11000/36545

Oral intake of Kluyveromyces marxianus B0399 plus Lactobacillus rhamnosus CECT 30579 to mitigate symptoms in COVID-19 patients: A randomized open label clinical trial

Título :
Oral intake of Kluyveromyces marxianus B0399 plus Lactobacillus rhamnosus CECT 30579 to mitigate symptoms in COVID-19 patients: A randomized open label clinical trial
Autor :
navarro-lopez, vicente  
Hernández Belmonte, Adriana  
Pérez Soto, Maria Isabel
Ayo González , Maikel  
Losa Rodríguez, Guillermo
Ros-Sánchez, Esther
Martínez Gabarrón, Maravillas
Sánchez-Pellicer, Pedro
Aguera Santos, Juan
Núñez-Delegido, Eva  
Ruzafa-Costas, Beatriz  
Pico-Monllor, JOSE ANTONIO  
Navarro-Moratalla, Laura
Editor :
Elsevier
Departamento:
Departamentos de la UMH::Farmacología, Pediatría y Química Orgánica
Fecha de publicación:
2022-08
URI :
https://hdl.handle.net/11000/36545
Resumen :
At the beginning of the SARS-CoV-2 pandemic, developing of new treatments to control the spread of infection and decrease morbidity and mortality are necessary. This prospective, open-label, case-control intervention study evaluates the impact of the oral intake of the probiotic yeast Kluyveromyces marxianus B0399 together with Lactobacillus rhamnosus CECT 30579, administered for 30 days, on the evolution of COVID-19 patients. Analysis of the digestive symptoms at the end of the follow up shows a benefit of the probiotic in the number of patients without pyrosis (100% vs 33.3%; p 0.05) and without abdominal pain (100% vs 62.5%; p 0.04). Results also show a better evolution when evaluating the difference in the overall number of patients without non-digestive symptoms at the end of the follow-up (41.7%, vs 13%; p 0.06). The percentage of improvement in the digestive symptoms (65% vs 88%; p value 0.06) and the global symptoms (digestive and non-digestive) (88.6% vs 70.8%; p value 0.03) is higher in the probiotic group. The probiotic was well tolerated with no relevant side effects and high adherence among patients. In conclusion, this coadjutant treatment seems to be promising, although results should be confirmed in new studies with higher number of patients.
Palabras clave/Materias:
COVID-19
SARS-CoV-2
Probiotics
Microbiota
Microbiome
Tipo de documento :
info:eu-repo/semantics/article
Derechos de acceso:
info:eu-repo/semantics/openAccess
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
DOI :
https://doi.org/10.1016/j.medmic.2022.100061
Aparece en las colecciones:
Artículos Farmacología, Pediatría y Química Orgánica



Creative Commons La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.